Economic evaluation of stapokibart for chronic rhinosinusitis with nasal polyps in China: a cost-effectiveness analysis.

内容摘要

Aim: To evaluate the cost-effectiveness of stapokibart compared with dupilumab in treating chronic rhinosinusitis with nasal polyps (CRSwNP) from the healthcare system perspective in China. The focus is on assessing the economic viability of biologic treatments in managing CRSwNP, particularly when conventional treatments and/or surgery fail to provide sufficient relief. Materials & methods: A decision tree Markov model was developed to assess the cost-effectiveness of stapokibart and dupilumab. Clinical data from multiple trials were used, and a matching-adjusted indirect comparison was conducted to account for differences in patient populations across studies. Sensitivity analysis was performed to evaluate the robustness of the model results under varying assumptions. Results: The study results indicate that stapokibart offers a clear economic advantage over dupilumab. It both lowers treatment costs and enhances patients' quality of life. Sensitivity analysis shows that stapokibart remains cost-effective at the threshold of one to three-times China's per capita GDP, demonstrating strong economic viability in the Chinese healthcare context. Conclusion: The study demonstrates that stapokibart is a cost-effective treatment option for CRSwNP compared with dupilumab. It offers significant improvements in patient outcomes and is economically viable under the prevailing healthcare budget in China, providing valuable insights for policy-makers and healthcare providers. What is this article about? In China, stapokibart and dupilumab are biologic treatments for chronic rhinosinusitis with nasal polyps, a long-term condition that can seriously affect how people feel and live. For some patients, standard medicines or surgery do not provide enough relief, and biologic treatments may then be considered. However, these treatments are expensive, so it is important to understand which option provides better value. To assess the economic value of stapokibart compared with dupilumab, this study evaluated the costs and health outcomes of the two treatments from the healthcare system perspective in China. Because there was no direct clinical trial comparing stapokibart with dupilumab, data from separate clinical studies were used and adjusted to make the comparison as fair as possible. What were the results? The results showed that stapokibart was associated with lower overall treatment costs and better health outcomes than dupilumab in the main analysis. Additional analyses also showed that the findings remained stable under different assumptions. When the price difference between the two drugs was removed, stapokibart was no longer cost-saving, but it still remained cost-effective. What do the results mean? These findings suggest that stapokibart may offer an economic advantage over dupilumab for patients with chronic rhinosinusitis with nasal polyps in China. The results may help support treatment selection and medical insurance decision-making in clinical practice.